Grants and Contracts Details
| Status | Finished |
|---|---|
| Effective start/end date | 11/8/21 → 9/18/23 |
Funding
- Jounce Therapeutics Incorporated: $31,886.00
Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) In
- Myint, Zin (PI)
- Chauhan, Aman (Former PI)